G20 summit: PM Modi to hold 15 bilateral meetings over 3 days

Himanta Sarma’s Big Claims: 'If BJP Wins 400 Seats, Will Construct Gyanvapi And Mathura Temples'

Assam CM Himanta Biswa Sarma has stirred controversy with his remarks in Delhi, stating that with 400 seats, his party aims to build Krishna Janmabhoomi and Baba Vishwanath Mandir, in addition to Ram Mandir. He criticised Congress, alleging no discussions in Parliament regarding PoK during their rule. Sarma asserted that under PM Modi's leadership, Pak-occupied Kashmir will soon become part of India. #BJP #HimantaSarma #Elections2024 #GyanvapiTemple #MathuraTemple #RamMandir #KrishnaJanmabhoomi #VishwanathMandir #PoliticalClaims #India2024 #IndianPolitics #BJPVision #ElectionPromises #Hinduism #TempleConstruction ~PR.152~ED.155~GR.124~HT.96~

Who is Sending Bomb Threats to Indian Schools? After Delhi & Lucknow, Kanpur Receives Shocking Email

Several schools in Kanpur, Uttar Pradesh, have received bomb threats via email, sparking concern and prompting a swift police investigation. Joint Commissioner of Police (Law and Order) Harish Chander assured parents that precautionary measures are being taken and urged them not to panic. Stay updated with the latest developments on this evolving situation. #Kanpur #KanpurNews #KanpurSchools #KanpurSchoolsThreat #KanpurSchoolEmail #Delhi #Lucknow #HoaxMail #LatestUpdate #NewsBreak #BreakingNews #NewsAlert #Oneindia ~HT.99~PR.274~ED.155~

Macron invites Chinese leader Xi to visit the French Pyrenees

The meeting of the two leaders at a remote mountain pass follows a high-stakes visit in Paris.

Putin's Fear Rattles NATO: Macron Says Won't Fight Russia After Russia Deploys Nukes Near Kyiv

French President Emmanuel Macron clarified on Monday that the US and its allies have no intentions of seeking regime change in Russia. However, Paris remains committed to supporting Kiev in its ongoing conflict with Moscow, pledging continued aid for as long as necessary. Macron's remarks came during a joint press conference with Chinese President Xi Jinping at the Elysee Palace, where they engaged in discussions alongside the President of the European Commission, Ursula von der Leyen. Among the topics addressed were the Ukraine conflict, bilateral trade, and economic relations between France and China. In his statements, Macron emphasised the importance of dialogue and cooperation in addressing global challenges, underscoring the need for diplomatic solutions to complex geopolitical issues. #Macron #France #Russia #UkraineWar #NuclearDeployment #TacticalWeapons #Diplomacy #Geopolitics #InternationalRelations #XiJinping #Meeting #PeaceEfforts #ConflictResolution #GlobalSecurity #News ~HT.178~PR.152~ED.101~GR.124~

Macron seeks to charm China's Xi into trade concessions in Pyrenees jaunt

Georgia's prime minister says 'Russian law' necessary for peace as protests continue

The White House said it was "deeply troubled" that parliament had passed the bill. The UK, Germany, Italy and France have also all urged Georgia to withdraw it.

Co-leader of Germany's far-right AfD party fined for using Nazi slogan

The case involved Björn Höcke's use of "Everything for Germany!" in a 2021 speech. While prosecutors said he knew it was originally a Nazi slogan, Höcke claimed it was an "everyday saying".

New Analysis Suggests Long-Term Effectiveness for Wegovy Users

New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users . NBC reports that patients taking Novo Nordisk's obesity treatment maintain an average of 10% weight loss over four years. The news potentially boosts the drugmaker's push for Wegovy to be covered by insurers and governments. . The company submitted long-term findings at the European Congress on Obesity in Venice, Italy. . This is the longest study we’ve conducted so far of semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC. We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC. According to another analysis published by the drugmaker, approximately 17% of trial participants stopped using the treatment due to side effects like nausea. . The costly treatment ranges from $200 to nearly $2,000 per month in the ten countries where the drug is available. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. Rival Eli Lilly launched its drug Zepbound in the United States in December of 2023. . Neither drugmaker has managed to produce enough of the treatment to meet surging demand

European Commission chief von der Leyen visits Rome as campaign trail continues

Prior to her Monday meetings with Italian political leaders, von der Leyen was a guest on national TV, where she spoke about the need to defend Ukraine against Russia's aggression to preserve peace in Europe.